Blueline Advisors’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Blueline Advisors’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.1K	Buy	+78	New	+$8.44K	﹤0.01%	210

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

JGCM

Joseph Group Capital Management Columbus, Ohio $476M AUM 21.21% 1-Year Est. Return

Blueline Advisors's PJP Position: Q2 2026 in Review

Blueline Advisors opened a new position in Invesco Pharmaceuticals ETF (PJP) in Q2 2026: 78 shares worth $6.1K. The stake represents ﹤0.01% of the portfolio and ranks #210 among its holdings.

117 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

Blueline Advisors held 78 shares of Invesco Pharmaceuticals ETF worth $6.1K as of Q2 2026.
Invesco Pharmaceuticals ETF was a new Blueline Advisors position in Q2 2026.
Invesco Pharmaceuticals ETF made up ﹤0.01% of Blueline Advisors's portfolio in Q2 2026, its #210 holding.
117 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on Blueline Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.